Successful treatment by CAR T-cells in multi-refractory mantle cell lymphoma with central nervous system involvement

Caillet, Adrien; Houillier, Caroline; Sourdeau, Elise; Gazzano, Marianne; Uzunov, Madalina; Friser, Valérie; Ribeiro, Monica; Nicelli, Lucia; Azar, Nabih; Baron, Marine; Phina-Ziebin, Xavier; Choquet, Sylvain; Roos-Weil, Damien

doi:10.1007/s00277-023-05408-x

Ann Hematol

2023

DOI: 10.1007/s00277-023-05408-x

|View full text |Cite

Successful treatment by CAR T-cells in multi-refractory mantle cell lymphoma with central nervous system involvement

Adrien Caillet,

Caroline Houillier,

Elise Sourdeau

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Brexucabtagene-autoleucel/ibrutinib/lenalidomide

2024

Reactions Weekly

View full text Add to dashboard Cite

Brexucabtagene-autoleucel/ibrutinib/lenalidomide

2024

Reactions Weekly

View full text Add to dashboard Cite

Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement

Lionel,

Gurumurthi,

Fetooh

et al. 2024

Leukemia & Lymphoma

View full text Add to dashboard Cite

Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Barraclough,

Tang,

Lasica

et al. 2024

Internal Medicine Journal

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) is a clinically heterogeneous B‐cell neoplasm with unique clinicopathological features, accounting for 5% of all non‐Hodgkin lymphoma. Although for many chemoimmunotherapy can lead to durable remissions, those with poor baseline prognostic factors, namely blastoid morphology, TP53 aberrancy and Ki67 >30%, will have less durable responses to conventional therapies. With this in mind, clinical trials have focused on novel targeted therapies to improve outcomes. This review details the recent advances in the understanding of MCL biology and outlines the recommended diagnostic strategies and evidence‐based approaches to treatment.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Successful treatment by CAR T-cells in multi-refractory mantle cell lymphoma with central nervous system involvement

Cited by 4 publications

References 10 publications

Brexucabtagene-autoleucel/ibrutinib/lenalidomide

Brexucabtagene-autoleucel/ibrutinib/lenalidomide

Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement

Diagnosis and management of mantle cell lymphoma: a consensus practice statement from the Australasian Lymphoma Alliance

Contact Info

Product

Resources

About